Stephen D. Dickson1, Esad Vucic1,2,
Claudia Calcagno1, James HF Rudd1, James Lin1,
Jessica Mounessa1, Michelle Roytman1, Zahi A. Fayad1,2
1Radiology, Mount Sinai School of
Medicine, New York, NY, United States; 2Medicine, Mount Sinai
School of Medicine, New York, NY, United States
Dynamic
contrast enhanced (DCE) MRI and F18-fluorodeoxyglucose (FDG) PET/CT was
performed on control and pioglitazone-treated atherosclerotic New Zealand
White Rabbits at three time points over three months. After three months,
treated animals showed decreased MRI contrast agent uptake in plaque as well
as decreased FDG signal as compared to controls. Macrophage specific
immuno-histochemistry validated anti-inflammatory observations.
Keywords